Table 1:
Baseline characteristics by AHA activity category and region (Americas)
| Poor Activity n=1312 | Intermediate Activity n=246 | Ideal Activity n=193 | P value (trend) | |
|---|---|---|---|---|
| Age | 71.6 ± 9.9 | 71.1 ± 9.4 | 72.2 ± 9.1 | 0.69 |
| Female | 671 (51.1) | 116 (47.2) | 84 (43.5) | 0.03 |
| Race | 0.27 | |||
| White | 1025 (78.1) | 188 (76.4) | 161 (83.4) | |
| Black | 229 (17.5) | 44 (17.9) | 23 (11.9) | |
| Inclusion Criteria | ||||
| HF Hospitalization | 756 (57.6) | 117 (47.6) | 93 (48.2) | 0.001 |
| BNP | 556 (42.4) | 129 (52.4) | 100 (51.8) | |
| Spironolactone | 655 (49.9) | 129 (52.4) | 96 (49.7) | 0.81 |
| LVEF | 58.2 ± 7.7 | 58.2 ± 7.4 | 57.6 ± 8.5 | 0.38 |
| NYHA Class | <0.001 | |||
| 1 | 70 (5.3) | 8 (3.3) | 20 (10.4) | |
| 2 | 742 (56.7) | 162 (65.9) | 134 (69.4) | |
| 3 | 487 (37.2) | 76 (30.9) | 39 (20.2) | |
| 4 | 10 (0.8) | - | - | |
| Overall KCCQ score (QOL) | 55.3 ±23.2 | 63.1 ±22.3 | 70.7 ±20.2 | <0.001 |
| Hypertension | 1186 (90.4) | 219 (89.0) | 169 (87.6) | 0.19 |
| Diabetes Mellitus | 616 (47.0) | 97 (39.4) | 68 (35.2) | <0.001 |
| Insulin use | 292 (47.4) | 51 (52.6) | 32 (47.1) | 0.72 |
| eGFR<60 ml/min/1.73 m2 | 661 (50.4) | 116 (47.2) | 73 (37.8) | <0.001 |
| Previous MI | 260 (19.8) | 54 (22.0) | 45 (23.3) | 0.2 |
| Previous HF hospitalization | 805 (61.4) | 128 (52.0) | 96 (49.7) | <0.001 |
| Previous CVA | 118 (9.0) | 23 (9.3) | 17 (8.8) | 1.00 |
| Atrial fibrillation | 547 (41.7) | 100 (40.7) | 93 (48.2) | 0.17 |
| Dyslipidemia | 912 (69.5) | 181 (73.6) | 148 (76.7) | 0.02 |
| COPD | 215 (16.4) | 39 (15.9) | 32 (16.6) | 0.98 |
| Smoking Status | 0.01 | |||
| Current | 82 (6.3) | 20 (8.1) | 14 (7.3) | |
| Past | 647 (49.3) | 136 (55.3) | 110 (57.0) | |
| Never | 583 (44.4) | 90 (36.6) | 69 (35.8) | |
| BMI, kg/m2 | 34.3 ± 8.6 | 32.9 ± 8.0 | 31.9 ± 6.9 | <0.001 |
| SBP, mmHg | 127.8 ± 16.2 | 127.1 ± 15.4 | 126.2 ± 14.1 | 0.18 |
| DBP, mmHg | 71.5 ± 11.7 | 71.6 ± 11.3 | 70.2 ± 10.3 | 0.24 |
| HR, beats/min | 69.4 ± 11.4 | 69.6 ± 10.8 | 65.9 ± 10.4 | <0.001 |
| BNP, pg/ml * | 260 [146, 462] n=490 | 234 [152, 415] n=127 | 280 [195, 410] n=69 | 0.73 |
| NT-proBNP, pg/ml * | 974 [585, 2101] n=284 | 976 [695, 1797] n=32 | 763 [479, 1720] n=43 | 0.35 |
| Hemoglobin, g/dl | 12.8 ± 1.7 | 13.0 ± 1.6 | 13.2 ± 1.5 | <0.001 |
| Potassium, mmol/l | 4.2 ± 0.4 | 4.2 ± 0.4 | 4.3 ± 0.4 | 0.06 |
| Creatinine, mg/dl | 1.2 ± 0.3 | 1.2 ± 0.3 | 1.1 ± 0.3 | 0.03 |
| Medication use | ||||
| Beta-blocker | 1023 (78.0) | 198 (80.5) | 156 (80.8) | 0.27 |
| Calcium channel blocker | 509 (38.8) | 102 (41.5) | 65 (33.7) | 0.38 |
| Diuretic | 1176 (89.7) | 219 (89.0) | 165 (85.5) | 0.10 |
| ACE-I/ARB | 1048 (79.9) | 192 (78.0) | 141 (73.1) | 0.03 |
| Aspirin | 770 (58.7) | 136 (55.3) | 114 (59.1) | 0.75 |
Data reported as n (%) or mean ± standard deviation or median [interquartile range].
Among those enrolling via BNP stratum. In the overall study, the study-qualifying BNP or NT-pro-BNP values were reported in 88.5% patients enrolled in this stratum; values were not collected for 11.5% who were enrolled before a change to the enrollment form was implemented in August 2007.
MI-myocardial infarction, HF-heart failure, BNP-brain natriuretic peptide, LVEF-left ventricular ejection fraction, NYHA-New York Heart Association, KCCQ (QOL)-Kansas City Cardiomyopathy Questionnaire (Quality of Life), eGFR- estimated glomerular filtration rate, CVA-cerebrovascular accident, COPD-chronic obstructive pulmonary disease. BMI-body mass index, SBP-systolic blood pressure, DBP-diastolic blood pressure, HR-heart rate, BNP-brain natriuretic peptide, NT-pro-BNP-N-terminal pro-BNP, ACE-I-angiotensin-converting enzyme inhibitor, ARB-angiotensin receptor blocker